Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Mustas

Physician Assistant Waukesha, WI Physician Assistant

NPI 1629080932 CMS profile 10684020

1111 Delafield St Ste 215, Waukesha, WI 53188

Open in the dashboard

General payments

$4,872

188 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Mustas of Waukesha, WI is reported in the CMS Open Payments database as having received $4,872 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $134 6
2024 General $604 30
2023 General $1,483 48
2022 General $1,814 69
2021 General $836 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Mustas
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to William Mustas were reported at $134. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year William Mustas Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $836 $132 $37–$438 $132
2022 $1,814 $155 $48–$522 $149
2023 $1,483 $167 $52–$557 $160
2024 $604 $178 $55–$600 $164
2025 $134 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Astellas Pharma US Inc $1,485 56 payments
  2. Janssen Biotech, Inc. $445 8 payments
  3. Pfizer Inc. $361 20 payments
  4. Teleflex LLC $272 4 payments
  5. Endo Pharmaceuticals Inc. $266 13 payments
  6. Halozyme Inc $250 9 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $215 10 payments
  8. Antares Pharma, Inc. $210 6 payments
  9. Sumitomo Pharma America, Inc. $207 15 payments
  10. Axonics Modulation Technologies, Inc. $171 8 payments
  11. Other $990 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,351 181 payments
  2. Education $503 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17 1 payment
Products named General payments · program years 2021–2025
  1. XTANDI $920 47 payments
  2. XYOSTED $460 15 payments
  3. ERLEADA $445 8 payments
  4. MYRBETRIQ $394 22 payments
  5. ORGOVYX $361 20 payments
  6. GEMTESA $300 20 payments
  7. TLANDO $299 5 payments
  8. AVEED $266 13 payments
  9. Nubeqa $215 10 payments
  10. Xofigo $197 9 payments
  11. Other $2,165 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

513

Median for Physician Assistant: 241

Drug cost

$95,508

Median for Physician Assistant: $4,110

Branded share of claims

40.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 45 $47,231
Myrbetriq Mirabegron Brand 61 $42,289
Tamsulosin Hcl Generic 183 $1,736
Oxybutynin Chloride Er Oxybutynin Chloride Brand 47 $1,132
Testosterone Cypionate Generic 21 $837
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 29 $737
Cephalexin Generic 27 $665
Ciprofloxacin Hcl Generic 39 $366
Sildenafil Citrate Generic 16 $210
Finasteride Generic 21 $184

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$6,252

Medicare's payments for the services billed

Medicare patients

95

Average age 77

Services billed

683

21 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 45%
Diabetes 34%
Chronic kidney disease 33%
Atrial fibrillation 28%
Depression 27%
Cancer 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $136
$136 45 —
XTANDI
  • Astellas Pharma US Inc $87
  • PFIZER INC. $26
$113 — —
ERLEADA
  • Janssen Biotech, Inc. $63
$63 — —
AKEEGA
  • Janssen Biotech, Inc. $63
$63 — —
XYOSTED
  • Antares Pharma, Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record